Merck & Co Inc
(FRA:6MK)
€
92.9
-0.2 (-0.21%)
Market Cap: 236.96 Bil
Enterprise Value: 261.27 Bil
PE Ratio: 21.36
PB Ratio: 5.93
GF Score: 78/100 Merck & Co Inc at SVB Leerink Global Healthcare (Virtual) Transcript
Feb 17, 2022 / 09:20PM GMT
Release Date Price:
€67.32
(-0.85%)
Daina Michelle Graybosch
SVB Leerink LLC, Research Division - MD of Immuno-Oncology & Senior Research Analyst
Hello, everyone. Welcome to our session this afternoon with Merck. I am really pleased to host Caroline Litchfield and Peter Dannenbaum.
And if you don't know me, I am the immuno-oncology analyst here at SVB Leerink. You may say, "Well, why do you cover Merck?" And it is because immuno-oncology is important to Merck. And actually, I love it because I love thinking about things other than immuno-oncology as well. And so always happy to talk with Merck management and really excited to have you both with us today.
Caroline Litchfield
Merck & Co., Inc. - Executive VP & CFO
Thank you, Daina.
Daina Michelle Graybosch
SVB Leerink LLC, Research Division - MD of Immuno-Oncology & Senior Research Analyst
And one point of process for people listening, if you'd like me to pose a question to Caroline or Peter, please look at the box below my finger, put it there. If you e-mail it to me, I
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot